MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies
March 19 2024 - 1:00PM
Business Wire
- Poster will present characterization of metabolites produced by
MaaT034 and its immunomodulatory effects on host cells.
- The new data strengthens previous promising findings shared at
the Society for Immunotherapy of Cancer (SITC) conference in
November 2023 and supports further development and advancement of
MaaT034 toward clinical trials.
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage
biotechnology company and a leader in the development of Microbiome
Ecosystem TherapiesTM (MET) dedicated to enhancing survival for
patients with cancer, will present new in vitro data at the
American Association for Cancer Research (AACR) Annual Meeting
2024, taking place on April 5-10 in San Diego, California.
MaaT034, a ground-breaking full ecosystem synthetic microbiota
product, is the first candidate coming from the Company’s MET-C
platform. Produced using a co-culturing technology and for large
scale manufacturing, MaaT034 is being developed to improve
responses to immunotherapy for patients with solid tumors in
combination with an ICI (Immune Checkpoint Inhibitors) treatment.
The first-in-human study is planned for 2025, with clinical batches
currently being produced in 2024.
The Company will detail the new preclinical data in a press
release on Monday, April 8th, 2024.
AACR Poster Presentation details:
- Title: Evaluation of a new co-cultured microbiome ecosystem
therapy candidate (MaaT034) for clinical testing as
adjuvant/neoadjuvant to immune checkpoint inhibitors in solid
tumors
- Session Category: Immunology
- Session Title: Microbiome, Inflammation, and Cancer
- Session Date and Time: Wednesday Apr 10, 2024, 9:00 AM - 12:30
PM
- Location: Poster Section 2
- Poster Board Number: 18
- Published Abstract Number: 6687
About MaaT Pharma
MaaT Pharma, a clinical-stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single-arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240319207572/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications – Corporate Communications Jacob
VERGHESE or Priscillia PERRIN +49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Aug 2023 to Aug 2024